Should I buy or sell Bio-Techne stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TECH shares. View TECH analyst ratings or view top-rated stocks .

What is Bio-Techne's stock price target for 2024?

10 brokers have issued 1-year price objectives for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they anticipate the company's stock price to reach $91.80 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price. View analysts price targets for TECH or view top-rated stocks among Wall Street analysts .

How have TECH shares performed in 2023?

Bio-Techne's stock was trading at $82.88 at the beginning of the year. Since then, TECH stock has decreased by 23.7% and is now trading at $63.27. View the best growth stocks for 2023 here .

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our TECH earnings forecast .

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Tuesday, October, 31st. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.39 by $0.04. The biotechnology company had revenue of $276.94 million for the quarter, compared to the consensus estimate of $289.81 million. Bio-Techne had a trailing twelve-month return on equity of 14.89% and a net margin of 21.57%.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Tuesday, October 31st. Stockholders of record on Friday, November 10th will be given a dividend of $0.08 per share on Friday, November 24th. This represents a $0.32 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, November 9th. Read our dividend analysis for TECH .

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.51%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 16.16% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TECH .

What ETFs hold Bio-Techne's stock?

ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include American Century Mid Cap Growth Impact (MID) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , VanEck Biotech ETF (BBH) , BlackRock Future Innovators ETF (BFTR) , Putnam BioRevolution ETF (SYNB) , Fidelity Disruptive Medicine ETF (FMED) and Harbor Health Care ETF (MEDI) .

When did Bio-Techne's stock split?

Bio-Techne's stock split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com . Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX) , Gilead Sciences (gild) , NVIDIA (NVDA) , AbbVie (ABBV) , Amgen (AMGN) , Abbott Laboratories (ABT) , Cisco Systems (CSCO) , Johnson & Johnson (JNJ) , AT&T (T) and Boeing (BA) .

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bamco Inc. NY (3.40%), Morgan Stanley (2.09%), Bank of New York Mellon Corp (1.57%), Mackenzie Financial Corp (1.47%), William Blair Investment Management LLC (1.46%) and Ameriprise Financial Inc. (1.37%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow , Charles R Kummeth, Charles R Kummeth , Glenn Hedde, James Hippel , John L Higgins , Kim Kelderman , Norman David Eansor , Robert V Baumgartner and Roeland Nusse . View institutional ownership trends .

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences. Read More

Bio-Techne Stock Price, News & Analysis (NASDAQ:TECH)

$63.13

+1.47 (+2.38%)

(As of 12:43 PM ET)

Compare

Today's Range: $62.10
▼
$63.42
50-Day Range: $52.83
▼
$70.87
52-Week Range: $51.79
▼
$89.91

Volume: 363,623 shs
Average Volume: 1.01 million shs
Market Capitalization: $9.98 billion

P/E Ratio: 41.53
Dividend Yield: 0.51%
Price Target: $91.80

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 45.1% Upside
$91.80 Price Target
Short Interest: Healthy
1.83% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.37
Upright™ Environmental Score
News Sentiment: 1.23
Based on 4 Articles This Week
Insider Trading: Selling Shares
$717,980 Sold Last Quarter
Proj. Earnings Growth: 21.47%
From $1.63 to $1.98 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.23 out of 5 stars

Medical Sector

7th out of 949 stocks

Biological Products, Except Diagnostic Industry

2nd out of 162 stocks

3.4

Analyst's Opinion

Consensus Rating
Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $91.80, Bio-Techne has a forecasted upside of 45.1% from its current price of $63.27.
Amount of Analyst Coverage
Bio-Techne has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.83% of the outstanding shares of Bio-Techne have been sold short.
Short Interest Ratio / Days to Cover
Bio-Techne has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Techne has recently decreased by 10.49%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Bio-Techne has a dividend yield of 0.51%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bio-Techne has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Bio-Techne is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.16% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bio-Techne has received a 65.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Biochips" products. See details.
Environmental Sustainability
The Environmental Impact score for Bio-Techne is -1.37.

2.4

News and Social Media Coverage

News Sentiment
Bio-Techne has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Bio-Techne this week, compared to 5 articles on an average week.
Search Interest
Only 4 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 85 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $717,980.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Bio-Techne is held by insiders.
Percentage Held by Institutions
94.64% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Bio-Techne are expected to grow by 21.47% in the coming year, from $1.63 to $1.98 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Techne is 41.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.81.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Techne is 41.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.29.
Price to Earnings Growth Ratio
Bio-Techne has a PEG Ratio of 5.28. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bio-Techne has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TECH Stock News Headlines

November 26, 2023 | americanbankingnews.com

Bio-Techne Co. (NASDAQ:TECH) Given Consensus Rating of "Moderate Buy" by Analysts

November 24, 2023 | benzinga.com

Advancing with Stability: Bio-Techne Benefits Investors with Growing Earnings and Stable Payouts

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 23, 2023 | finance.yahoo.com

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

November 22, 2023 | benzinga.com

Cystatin C Assay Market worth $540 million by 2028

November 20, 2023 | seekingalpha.com

Bio-Techne: Quality Play Struggles But Looks More Compelling

November 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Match Group (MTCH), IPG Photonics (IPGP) and Bio-Techne (TECH)

November 1, 2023 | startribune.com

Shareholders take stand against Bio-Techne's executive pay plan

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 1, 2023 | finance.yahoo.com

Bio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Call Transcript

October 31, 2023 | markets.businessinsider.com

Bio-Techne Corp. Q1 Profit Decreases, misses estimates

October 31, 2023 | finanznachrichten.de

Bio-Techne Corporation: Bio-Techne Releases First Quarter Fiscal 2024 Results

October 31, 2023 | msn.com

Bio-Techne declares $0.08 dividend

October 31, 2023 | finance.yahoo.com

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2024 RESULTS

October 31, 2023 | finance.yahoo.com

Bio-Techne's quarterly profit misses estimates as biotech funding woes persist

October 31, 2023 | finance.yahoo.com

Bio-Techne Corp (TECH) Reports 2% Organic Revenue Growth in Q1 FY2024

October 30, 2023 | msn.com

Bio-Techne Q1 2024 Earnings Preview

October 30, 2023 | markets.businessinsider.com

Here's what to expect from Bio-Techne's earnings

October 25, 2023 | finance.yahoo.com

LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING

October 23, 2023 | finance.yahoo.com

Bio-Techne (NASDAQ:TECH) sheds 6.6% this week, as yearly returns fall more in line with earnings growth

October 20, 2023 | startribune.com

Minneapolis-based Bio-Techne names new CEO

October 20, 2023 | insidermonkey.com

Various Headwinds Pressured Bio-Techne Corporation (TECH) Shares in Q3

October 19, 2023 | marketwatch.com

Bio-Techne Names Kelderman to Succeed Kummeth as President, CEO

October 19, 2023 | msn.com

Bio-Techne appoints Kelderman as CEO, as Kummeth retires

October 19, 2023 | markets.businessinsider.com

Bio-Techne Promotes Kim Kelderman To Succeed Chuck Kummeth As President And CEO

October 19, 2023 | finance.yahoo.com

BIO-TECHNE APPOINTS KIM KELDERMAN AS CHIEF EXECUTIVE OFFICER

October 16, 2023 | finance.yahoo.com

BIO-TECHNE ACHIEVES ISO 13485 CERTIFICATION FOR ITS WALLINGFORD, CT MANUFACTURING FACILITY

See More Headlines

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/1 Dividend: 8/17/2023
Dividend Payable: 9/01/2023
Last Earnings: 10/31/2023
Ex-Dividend for 11/24 Dividend: 11/09/2023
Dividend Payable: 11/24/2023
Today: 11/29/2023
Next Earnings (Estimated): 2/01/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:TECH
CUSIP: 87837710
CIK: 842023
Web: www.bio-techne.com
Phone: (612) 379-8854
Fax: 612-656-4400
Employees: 3,050
Year Founded: 1981

Price Target and Rating

Average Stock Price Target: $91.80
High Stock Price Target: $120.00
Low Stock Price Target: $65.00
Potential Upside/Downside: +48.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.52
Trailing P/E Ratio: 40.57
Forward P/E Ratio: 37.83
P/E Growth: 5.28
Net Income: $285.26 million
Net Margins: 21.57%
Pretax Margin: 24.87%
Return on Equity: 14.89%
Return on Assets: 11.05%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 4.63
Quick Ratio: 3.17

Sales & Book Value

Annual Sales: $1.14 billion
Price / Sales: 8.58
Cash Flow: $2.49 per share
Price / Cash Flow: 24.74
Book Value: $12.63 per share
Price / Book: 4.88

Miscellaneous

Outstanding Shares: 158,150,000
Free Float: 151,666,000
Market Cap: $9.75 billion
Optionable: Optionable
Beta: 1.22

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Charles R. Kummeth (Age 63)
CEO, President & Director
Comp: $1.26M
Mr. James T. Hippel (Age 52)
Executive VP of Finance & CFO
Comp: $691.78k
Mr. Kim Kelderman (Age 56)
Chief Operating Officer
Comp: $845.71k
Mr. Shane Bohnen (Age 48)
Senior VP, General Counsel & Corporate Secretary
Comp: $353.6k
Mr. William A. Geist (Age 53)
President of Protein Sciences Segment
Comp: $533.67k
David Clair
Senior Director of Investor Relations & Corporate Development
Mr. Gerry Andros
Vice President of Sales and Marketing
Mr. Robert M. Gavin (Age 55)
Vice President of Corporate Development
Comp: $724.51k
Ms. Brenda S. Everson
Senior VP & Chief Human Resources Officer
Mr. Luca Cicchetti
Managing Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.
What is Bio-Techne's stock price target for 2024?: 10 brokers have issued 1-year price objectives for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they anticipate the company's stock price to reach $91.80 in the next twelve months. This suggests a possible upside of 45.1% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.
How have TECH shares performed in 2023?: Bio-Techne's stock was trading at $82.88 at the beginning of the year. Since then, TECH stock has decreased by 23.7% and is now trading at $63.27.
View the best growth stocks for 2023 here.
When is Bio-Techne's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our TECH earnings forecast.
How were Bio-Techne's earnings last quarter?: Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings results on Tuesday, October, 31st. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.39 by $0.04. The biotechnology company had revenue of $276.94 million for the quarter, compared to the consensus estimate of $289.81 million. Bio-Techne had a trailing twelve-month return on equity of 14.89% and a net margin of 21.57%.
How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?: Bio-Techne announced a quarterly dividend on Tuesday, October 31st. Stockholders of record on Friday, November 10th will be given a dividend of $0.08 per share on Friday, November 24th. This represents a $0.32 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Thursday, November 9th.
Read our dividend analysis for TECH.
Is Bio-Techne a good dividend stock?: Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.51%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 16.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.
What ETFs hold Bio-Techne's stock?: ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include American Century Mid Cap Growth Impact (MID), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Putnam BioRevolution ETF (SYNB), Fidelity Disruptive Medicine ETF (FMED) and Harbor Health Care ETF (MEDI).

When did Bio-Techne's stock split?: Bio-Techne's stock split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.
What is Charles Kummeth's approval rating as Bio-Techne's CEO?: 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Bio-Techne own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).
Who are Bio-Techne's major shareholders?: Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bamco Inc. NY (3.40%), Morgan Stanley (2.09%), Bank of New York Mellon Corp (1.57%), Mackenzie Financial Corp (1.47%), William Blair Investment Management LLC (1.46%) and Ameriprise Financial Inc. (1.37%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.
How do I buy shares of Bio-Techne?: Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Bio-Techne have any subsidiaries?: The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More

This page (NASDAQ:TECH) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bio-Techne Stock Price, News & Analysis (NASDAQ:TECH)

Bio-Techne MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bio-Techne Stock (NASDAQ:TECH)

TECH Stock Price History

TECH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

TECH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™